Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.
B. Grana
No relevant relationships to disclose
H. A. Burris
No relevant relationships to disclose
J. Rodon Ahnert
No relevant relationships to disclose
A. R. Abdul Razak
No relevant relationships to disclose
M. J. De Jonge
No relevant relationships to disclose
F. Eskens
No relevant relationships to disclose
L. L. Siu
Research Funding - GlaxoSmithKline; Novartis; Pfizer
Q. C. Ru
Employment or Leadership Position - Novartis
N. F. Homji
Employment or Leadership Position - Novartis
D. Demanse
Employment or Leadership Position - Novartis
E. Di Tomaso
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. G. C. E. Cosaert
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
C. Quadt
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. Baselga
Consultant or Advisory Role - Novartis
J. C. Bendell
No relevant relationships to disclose